These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28203098)

  • 1. Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.
    Watson C; Prosser C; Braun S; Landsman-Blumberg PB; Gleissner E; Naoshy S
    Clinicoecon Outcomes Res; 2017; 9():85-97. PubMed ID: 28203098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
    Bonafede MM; Johnson BH; Watson C
    Clinicoecon Outcomes Res; 2013; 6():11-20. PubMed ID: 24379685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
    Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
    Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis.
    Pardo G; Pineda ED; Ng CD; Sheinson D; Bonine NG
    J Health Econ Outcomes Res; 2022; 9(1):111-116. PubMed ID: 35586512
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
    Burks J; Marshall TS; Ye X
    Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
    Taheri S; Sahraian MA; Yousefi N
    J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
    Freeman L; Kee A; Tian M; Mehta R
    Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
    Jones E; Pike J; Marshall T; Ye X
    BMC Health Serv Res; 2016 Jul; 16():294. PubMed ID: 27443278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment.
    Ziemssen T; Prosser C; Haas JS; Lee A; Braun S; Landsman-Blumberg P; Kempel A; Gleißner E; Patel S; Huang MY
    BMC Neurol; 2017 Mar; 17(1):62. PubMed ID: 28347283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.